Sign In  |  Register  |  About Corte Madera  |  Contact Us

Corte Madera, CA
September 01, 2020 10:27am
7-Day Forecast | Traffic

  • Search Hotels in Corte Madera

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S ADR (NY: NVO )

108.67 +1.87 (+1.75%)
Official Closing Price Updated: 4:10 PM EST, Dec 2, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S ADR

< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
65 66 Next >
Stock-Split Watch: 2 Healthcare Stocks That Look Ready to Split
Revenue is climbing at these two drug companies -- and the trend should continue. 
Via The Motley Fool
2 Incredibly Cheap Growth Stocks to Buy Now
Price is just one factor to consider. 
Via The Motley Fool
Is Eli Lilly a Good Dividend Stock to Buy Now?
A leading anti-obesity treatment plus a new Alzheimer's drug could drive profits through the roof. 
Via The Motley Fool
This 1 Piece of Bad News for Novo Nordisk Is Good News for Eli Lilly Stock
A new study raises important implications regarding the competitive balance between these two companies. 
Via The Motley Fool
Here's 80 Billion More Reasons to Buy Novo Nordisk Stock
Hopes are high about one of its next-gen candidates. 
Via The Motley Fool
The 7 Most Important Stocks to Watch as Q2 Earnings Season Kicks Off
Seven Q2 earnings season stocks are powered by catalysts that could have a major impact on their companies fortunes. 
Via InvestorPlace
Did Eli Lilly Just Get a Leg Up on Novo Nordisk?
Eli Lilly's latest milestone sets it apart from its rival Novo Nordisk. 
Via The Motley Fool
The Weight Loss Market Can Surge To $400B By 2032, And These Stocks Will Rule It
Despite Novo Nordisk's momentum, Eli Lilly seems a better long-term bet. Pfizer could surprise everyone from an undervalued position. 
Via Talk Markets
Novo Nordisk Stock Pops After Weight-Loss Drug Cuts Dementia Risk In Yearlong Study
A yearlong study at the University of Oxford suggests GLP-1 drugs could play a role in protecting brain health. 
Via Investor's Business Daily
Stock Market Shifts Toward Small Caps After Tame CPI; JPMorgan, Taiwan Semi, Tesla In Focus: Weekly Review
Megacaps and chip plays tumbled Thursday, but mostly still have healthy charts. 
Via Investor's Business Daily
Using Ozempic, Zepbound Or Other Weight Loss Drugs? Inform Doctors Before Anesthesia Or Surgery, European Medicines Agency Issues Advisory
EMA advises patients on GLP-1 weight-loss drugs like Wegovy to inform their doctors before surgery due to potential respiratory risks. New warnings to be included in product information to ensure... 
Via Benzinga
3 Global Stocks Worth Buying as America Stumbles
It never hurts to diversify your portfolio by adding global stocks, even if America doesn’t fall into the abyss. 
Via InvestorPlace
The 3 Most Undervalued Pharma Stocks to Buy in July 2024
Pharma stocks can be great investments during times of growth and recession, and are made even better if the stock is undervalued. 
Via InvestorPlace
Topics Economy
Exposures Economy
Novo Nordisk's 'Miracle' Weight Loss Drug Ozempic Linked To 48% Lower Risk Of Dementia, Study Finds
Novo Nordisk has found that its diabetes drug, Ozempic, is linked to a significant reduction in the risk of dementia and other cognitive issues. 
Via Benzinga
Eli Lilly, Novo Nordisk Shares Dip As Pfizer Ramps Up Diabetes Drug Competition
Shares of Eli Lilly and Co (NYSE: LLY) and Novo Nordisk A/S (NYSE: NVO) are facing declines Thursday, maybe influenced by competitive developments and regulatory updates in the pharmaceutical sector. 
Via Benzinga
Bernie Sanders Targets High Prices of Ozempic and Wegovy In US
Senator Bernie Sanders is pushing Novo Nordisk to lower U.S. prices for weight-loss drugs Ozempic and Wegovy, as part of a broader effort to reduce drug costs and expand Medicare price negotiations. 
Via Benzinga
FDA Rejects Novo Nordisk's Weekly Insulin, Requests Information Related To Manufacturing Process, Type 1 Diabetes
The FDA has issued a Complete Response Letter to Novo Nordisk's Biologics License Application for once-weekly basal insulin icodec. Novo Nordisk aims to address the FDA's requests but anticipates... 
Via Benzinga
Exposures Product Safety
EXCLUSIVE: Vivani Medical Outlines Plans To Kickstart First Clinical Study For Miniature GLP-1 Obesity Implant Program This Year
Vivani Medical plans to start the first clinical study of the NPM-115 program in Australia in Q4 2024. The study will evaluate a 6-month GLP-1 implant for chronic weight management in obese or... 
Via Benzinga
Chipotle Just Did a Stock Split. History Says This Is What Might Happen Next.
Big-name stocks that have split their shares in recent years have generally done fairly well afterward. 
Via The Motley Fool
Jim Cramer Identifies Eight Companies Eyeing Trillion-Dollar Club — Elon Musk's Tesla, Eli Lilly Top Contenders
Jim Cramer has identified eight companies that could potentially reach a market cap of $1 trillion, including Elon Musk's Tesla, and Eli Lilly. 
Via Benzinga
3 Pharma Stocks That Could Make Your Grandchildren Rich
Investors might want to consider the top pharma stocks in the current environment as they are beating most others. 
Via InvestorPlace
Only 25% Patients Stick With Novo Nordisk's Wegovy Or Ozempic After 2 Years, A Study Shows; Company Calls Data Insufficient
A study shows that only one in four U.S. patients prescribed Novo Nordisk's weight-loss drugs Wegovy or Ozempic remain on the medication after two years, raising concerns about long-term adherence. 
Via Benzinga
Stay Away: Why Ginkgo Bioworks Stock Is Not for the Faint-Hearted
Ginkgo Bioworks stock is down, but this doesn't mean it's a bargain as Ginkgo Bioworks faces a serious delisting threat. 
Via InvestorPlace
Eli Lilly Stock Leads in GLP-1 Race with its Triple Agonist Drug
Global pharmaceutical company Eli Lilly & Co. (NYSE: LLY) has been in a GLP-1 arms race with its FDA-approved therapies Mounjaro and Zepbound. It's been 
Via MarketBeat
7 Bullish Stock Picks With the Potential to Turn $5K Into $50K
These high-potential stock picks each have 10X potential moving forward and are well worth understanding despite high prices in some cases. 
Via InvestorPlace
3 Stocks With the Potential to 10X Your Money
These three top high-growth potential stocks could offer substantial growth and give your portfolio a major boost. 
Via InvestorPlace
Eli Lilly Rose More Than 50% So Far This Year. Can It Soar Past $1,000 in the 2nd Half?
This pharma company is posting double-digit revenue growth. 
Via The Motley Fool
Eli Lilly's Mounjaro Outpaces Novo Nordisk's Ozempic In Weight Loss Effectiveness, Study Shows
Eli Lilly and Co has emerged victorious in the weight loss drug competition, in a recent study. The study found that patients on Lilly's Mounjaro lost more weight than those on Novo Nordisk's Ozempic. 
Via Benzinga
Patients Lost More Weight On Eli Lilly's Mounjaro Than Novo Nordisk's Ozempic
Patients lost more more weight on Mounjaro than Ozempic. 
Via Investor's Business Daily
3 Overlooked Giants-in-the-Making for Patient Investors
Consider buying into these overlooked growth stocks for long-term profits that will help to boost a portfolio and deliver riches. 
Via InvestorPlace
< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
65 66 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 CorteMadera.com & California Media Partners, LLC. All rights reserved.